InflaRx N.V.

Healthcare

NASDAQ:IFRX · NASDAQ Global Select

Market Cap $121.35M Beta 2.44 P/E (TTM) -2.3

$1.60 -4.76%

-$0.08 today

52W Low $0.74High $2.95

Vol 0.77M · Avg 1.74M

EPS (TTM)-$0.59

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+104.08%

Period High

$2.74

Period Low

$0.77

Latest

$1.60

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Sutro Biopharma, Inc.

NASDAQ:STRO

$278.70M

Shattuck Labs, Inc.

NASDAQ:STTK

$236.64M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

$211.08M

Connect Biopharma Holdings Limited

NASDAQ:CNTB

$133.48M

Context Therapeutics Inc.

NASDAQ:CNTX

$127.71M

Kalaris Therapeutics Inc

NASDAQ:KLRS

$80.98M

ImageneBio Inc

NASDAQ:IMA

$63.39M

Metagenomi, Inc. Common Stock

MGX

$45.18M

aTyr Pharma, Inc.

ATYR

$43.18M

Quince Therapeutics, Inc.

QNCX

$5.20M

What is the latest IFRX filing?

The latest filing shown is SC 13G dated May 14, 2026.

How many recent filings does IFRX have?

Intrinsic Alpha currently shows 20 recent filings for IFRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.